Skip to main content
Premium Trial:

Request an Annual Quote

Eksigent Licenses Microfluidics Technologies from Sandia Labs

NEW YORK, Aug 14 – Eksigent Technologies has announced that it has licensed Sandia National Laboratories’ microfluidics technology.

Eksigent and Sandia, both of Livermore, Calif., did not disclose the terms of the deal or describe the specific technologies involved. Sandia licensed Eksigent the technology through its tech transfer program.

Eksigent, which is developing the EKPump, an electrokinetic pump that uses an applied electric field to generate fluid flow and high pressures, said that it would initially use Sandia’s technology in its microfluidics system.

The technology could also be applied to proteomics and chemical analysis, the company said.

"Combined with additional efforts at Eksigent, this technology will soon be ready for integration into commercial products," Don Arnold, cofounder of Eksigent, said in a statement. 

Eksigent’s technical staff previously worked at Sandia, developing microfluidics systems. In July, Eksigent announced a deal to work with Beckman Coulter to jointly look for ways to incorporate its microfluidics technology into Beckman Coulter’s instruments. 

The Sandia lab, part of the US Department of Energy, conducts research in national security, energy, and environmental technologies.

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.